Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer

Meijia Yu; Yiming Wu; Qingfang Li; Weiqi Hong; Yang Yang; Xiaoyi Hu; Yanfei Yang; Tianqi Lu; Xia Zhao; Xiawei Wei

doi:10.1016/j.gendis.2023.04.023

您当前的位置：

首页 >

文章列表页 >

Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer

Full-length article | 更新时间：2024-02-04

- Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer
- Genes & Diseases Vol. 11, Issue 3, (2024)
- 作者机构：
  
  1. Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University,Sichuan,Chengdu,China,610041
  2. Department of Obstetrics and Gynecology, The First Affiliated Hospital, Army Medical University,Chongqing,China,400038
  3. Department of Gynecology and Obstetrics, Development and Related Disease of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University,Sichuan,Chengdu,China,610041
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.04.023
  CLC：
- Published：2024，
  
  Published Online：1 May 2024，
扫描看全文
Meijia Yu, Yiming Wu, Qingfang Li, et al. Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer. [J]. Genes & Diseases 11(3).(2024)
DOI：

Meijia Yu, Yiming Wu, Qingfang Li, et al. Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer. [J]. Genes & Diseases 11(3).(2024) DOI： 10.1016/j.gendis.2023.04.023.

摘要

Abstract

Ovarian cancer is the tumor with the highest mortality among gynecological malignancies. Studies have confirmed that paclitaxel chemoresistance is associated with increased infiltration of tumor-associated macrophages (TAMs) in the microenvironment. Colony-stimulating factor 1 (CSF-1) receptor (CSF-1R) plays a key role in regulating the number and differentiation of macrophages in certain solid tumors. There are few reports on the effects of targeted inhibition of CSF-1R in combination with chemotherapy on ovarian cancer and the tumor microenvironment. Here

we explored the antitumor efficacy and possible mechanisms of the CSF − 1R inhibitor pexidartinib (PLX3397) when combined with the first-line chemotherapeutic agent paclitaxel in the treatment of ovarian cancer. We found that CSF-1R is highly expressed in ovarian cancer cells and correlates with poor prognosis. Treatment by PLX3397 in combination with paclitaxel significantly inhibited the growth of ovarian cancer both

in vitro

and

in vivo

. Blockade of CSF-1R altered the macrophage phenotype and reprogrammed the immunosuppressive cell population in the tumor microenvironment.

关键词

Keywords

CSF-1ROvarian cancerPaclitaxelPLX3397Targeted therapyTumor-associated macrophages

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

The evolving roles of Wnt signaling in stem cell proliferation and differentiation, the development of human diseases, and therapeutic opportunities

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics

Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

Related Author

Michael Yu

Kevin Qin

Jiaming Fan

Guozhi Zhao

Piao Zhao

Wei Zeng

Connie Chen

Annie Wang

Related Institution

Ministry of Education Key Laboratory of Diagnostic Medicine, and Department of Clinical Biochemistry, The School of Laboratory Medicine, Chongqing Medical University

Department of Orthopedic Surgery, The First Affiliated Hospital of Chongqing Medical University

Molecular Oncology Laboratory, Department of Orthopedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center

Department of Orthopaedic Surgery, Chinese Academy of Medical Sciences & Peking Union Medical College

Department of Neurology, The First Dongguan Affiliated Hospital, Guangdong Medical University

⁰